Fig. 4

Dissection of single-cell subpopulations according to distinctive activation status of EGFR and Src pathways. a, b Single cells were manually ordered by categorization into four groups according to their activation status as shown in e. a Heatmaps showing the relative (upper) and binary (lower) activation status for EGFR and Src pathways in mRCC cells from parental and PDX tumors. b Predicted drug sensitivity of afatinib and dasatinib matched to a. c Comparison of the fraction of categorized single cells between parental and PDX tumors. d Differences in the estimated pathways with predicted drug sensitivity among the four classified groups. Boxes show 25th to 75th percentile with 10th and 90th percentile whiskers. *P <0.05, **P <0.01, ***P <0.001, two-tailed Student’s t-test. e Strategic combination therapy using afatinib and dasatinib to target the EGFR and Src signaling pathways, respectively